WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Police raid the headquarters of the Milan
CJ McCollum scores 28 points as Pelicans hold off Warriors 114
CJ McCollum scores 28 points as Pelicans hold off Warriors 114
Rudy Gobert's big night lifts Timberwolves past Hawks and into a first
Testimony at Sen. Bob Menendez's bribery trial focuses on his wife's New Jersey home
A Supreme Court social media ruling could set new free speech standards
Republicans debate ahead of runoff for Alabama congressional seat
He once swore off politics. Now, this Georgia activist is trying to recruit people who seldom vote
Tigers starter Olson leaves game against Royals after being struck by line drive
Trump says Arizona's abortion ban goes 'too far'
US Open champ Coco Gauff urges young Americans to vote
Trump’s hush money trial will test Alvin Bragg's efforts at neutrality